Global Subcutaneous Injection Market Size, Status and Forecast 2019-2025

2 Global Subcutaneous Injection Quarterly Market Size Analysis

• 2.1 Subcutaneous Injection Business Impact Assessment - COVID-19
  • 2.1.1 Global Subcutaneous Injection Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Subcutaneous Injection Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Subcutaneous Injection Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Subcutaneous Injection Headquarters and Area Served
• 3.3 Date of Key Players Enter into Subcutaneous Injection Market
• 3.4 Key Players Subcutaneous Injection Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Subcutaneous Injection Segments, By Type

• 4.1 Introduction
  • 1.4.1 Subcutaneous Injection Equipment
  • 1.4.2 Subcutaneous Injection Drug
  • 1.4.3 Others
• 4.2 By Type, Global Subcutaneous Injection Market Size, 2019-2021

5 Impact of Covid-19 on Subcutaneous Injection Segments, By Application

• 5.1 Overview
  • 5.5.1 Hospital
  • 5.5.2 Clinic
  • 5.5.3 Laboratory
  • 5.5.4 Others
• 5.2 By Application, Global Subcutaneous Injection Market Size, 2019-2021
  • 5.2.1 By Application, Global Subcutaneous Injection Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Becton Dickinson
  • 7.1.1 Becton Dickinson Business Overview
  • 7.1.2 Becton Dickinson Subcutaneous Injection Quarterly Revenue, 2020
  • 7.1.3 Becton Dickinson Subcutaneous Injection Product Introduction
  • 7.1.4 Becton Dickinson Response to COVID-19 and Related Developments
• 7.2 Daiichi Sankyo
  • 7.2.1 Daiichi Sankyo Business Overview
  • 7.2.2 Daiichi Sankyo Subcutaneous Injection Quarterly Revenue, 2020
  • 7.2.3 Daiichi Sankyo Subcutaneous Injection Product Introduction
  • 7.2.4 Daiichi Sankyo Response to COVID-19 and Related Developments
• 7.3 Sanofi
  • 7.3.1 Sanofi Business Overview
  • 7.3.2 Sanofi Subcutaneous Injection Quarterly Revenue, 2020
  • 7.3.3 Sanofi Subcutaneous Injection Product Introduction
  • 7.3.4 Sanofi Response to COVID-19 and Related Developments
• 7.4 Roche
  • 7.4.1 Roche Business Overview
  • 7.4.2 Roche Subcutaneous Injection Quarterly Revenue, 2020
  • 7.4.3 Roche Subcutaneous Injection Product Introduction
  • 7.4.4 Roche Response to COVID-19 and Related Developments
• 7.5 GSK
  • 7.5.1 GSK Business Overview
  • 7.5.2 GSK Subcutaneous Injection Quarterly Revenue, 2020
  • 7.5.3 GSK Subcutaneous Injection Product Introduction
  • 7.5.4 GSK Response to COVID-19 and Related Developments
• 7.6 Eli Lilly
  • 7.6.1 Eli Lilly Business Overview
  • 7.6.2 Eli Lilly Subcutaneous Injection Quarterly Revenue, 2020
  • 7.6.3 Eli Lilly Subcutaneous Injection Product Introduction
  • 7.6.4 Eli Lilly Response to COVID-19 and Related Developments
• 7.7 Asahi Kasei Pharma
  • 7.7.1 Asahi Kasei Pharma Business Overview
  • 7.7.2 Asahi Kasei Pharma Subcutaneous Injection Quarterly Revenue, 2020
  • 7.7.3 Asahi Kasei Pharma Subcutaneous Injection Product Introduction
  • 7.7.4 Asahi Kasei Pharma Response to COVID-19 and Related Developments
• 7.8 Takeda Pharmaceutical
  • 7.8.1 Takeda Pharmaceutical Business Overview
  • 7.8.2 Takeda Pharmaceutical Subcutaneous Injection Quarterly Revenue, 2020
  • 7.8.3 Takeda Pharmaceutical Subcutaneous Injection Product Introduction
  • 7.8.4 Takeda Pharmaceutical Response to COVID-19 and Related Developments
• 7.9 Antares Pharma, Inc.
  • 7.9.1 Antares Pharma, Inc. Business Overview
  • 7.9.2 Antares Pharma, Inc. Subcutaneous Injection Quarterly Revenue, 2020
  • 7.9.3 Antares Pharma, Inc. Subcutaneous Injection Product Introduction
  • 7.9.4 Antares Pharma, Inc. Response to COVID-19 and Related Developments
• 7.10 Eisai Co.，Ltd
  • 7.10.1 Eisai Co.，Ltd Business Overview
  • 7.10.2 Eisai Co.，Ltd Subcutaneous Injection Quarterly Revenue, 2020
  • 7.10.3 Eisai Co.，Ltd Subcutaneous Injection Product Introduction
  • 7.10.4 Eisai Co.，Ltd Response to COVID-19 and Related Developments
• 7.11 Chugai Pharmaceutical
  • 7.11.1 Chugai Pharmaceutical Business Overview
  • 7.11.2 Chugai Pharmaceutical Subcutaneous Injection Quarterly Revenue, 2020
  • 7.11.3 Chugai Pharmaceutical Subcutaneous Injection Product Introduction
  • 7.11.4 Chugai Pharmaceutical Response to COVID-19 and Related Developments
• 7.12 Endo International
  • 7.12.1 Endo International Business Overview
  • 7.12.2 Endo International Subcutaneous Injection Quarterly Revenue, 2020
  • 7.12.3 Endo International Subcutaneous Injection Product Introduction
  • 7.12.4 Endo International Response to COVID-19 and Related Developments
• 7.13 PenJet Corporation
  • 7.13.1 PenJet Corporation Business Overview
  • 7.13.2 PenJet Corporation Subcutaneous Injection Quarterly Revenue, 2020
  • 7.13.3 PenJet Corporation Subcutaneous Injection Product Introduction
  • 7.13.4 PenJet Corporation Response to COVID-19 and Related Developments
• 7.14 Aspen Medical Group
  • 7.14.1 Aspen Medical Group Business Overview
  • 7.14.2 Aspen Medical Group Subcutaneous Injection Quarterly Revenue, 2020
  • 7.14.3 Aspen Medical Group Subcutaneous Injection Product Introduction
  • 7.14.4 Aspen Medical Group Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US